Description
Springer Sandostatin® in the Treatment of Acromegaly Consensus Round Table Amsterdam 1987 1st Editon 2012 Softbound by Steven W.J. Lamberts
Acromegaly is a relatively rare chronic disease. Nevertheless, it is life-threatening in its sequelae, for example, hypertension and cardiovascular disease. Since it also has disfiguring properties - especially of the head and face - acromegaly has serious psychological consequences which are reinforced by the awareness of factors such as excessive sweating. It is precisely on these signs and symptoms that Sandostatin R has a rapid effect, thus improving the patient's quality of life as well as counteracting the underlying processes. SandostatinÊ 1. Clinical Aspects of Growth Hormone Hypersecretory States.- 2. Correlation Between Preoperative Testing and Tumour Morphology in Acromegaly.- 3. Acromegaly: Objectives of Therapy.- 4. Surgical Treatment of Acromegaly.- 5. External Radiation Therapy of Acromegaly.- 6. Bromocriptine Treatment of Acromegaly.- 7. Chemical Structure, Pharmacodynamic Profile and Pharmacokinetics of SMS 201-995 (Sandostatin®).- 8. Studies on the Acute and Chronic Effects of Sandostatin® in Acromegaly.- 9. Medical Treatment of Acromegaly. Dopaminergic Agonists and Long-Acting Somatostatin.- 10. Treatment of Acromegaly with the Somatostatin Analogue SMS 201-995 (Sandostatin®).- 11. Observations During a Clinical Trial of Sandostatin® in Acromegalic Patients.- 12. Effects of Long-Term Administration of Sandostatin® (SMS 201-995) at Increasing Doses in 40 Acromegalic Patients. Results from the French Sandostatin Acromegaly Study Group.- 13. Experience with Sandostatin® in Various Groups of Acromegalic Patients.- 14. Treatment of Acromegaly with SMS 201-995 (Sandostatin®): Clinical, Biochemical and Morphologic Study.- 15. Long-Term Treatment of Acromegaly by Continuous Subcutaneous Infusion of the Long-Acting Somatostatin Analog Sandostatin® (SMS 201-995, Octreotide).- 16. Sandostatin® (SMS 201-995) Treatment of Acromegaly: Acute and Chronic Effects.- 17. Long-Term Efficacy of Sandostatin® (SMS 201-995, Octreotide) in 178 Acromegalic Patients. Results from the International Multicentre Acromegaly Study Group.- 18a. Pulsatile Administration of SMS 201-995 (Sandostatin®) in the Treatment of Acromegaly.- 18b. Treatment of Acromegaly with SMS 201-995 (Sandostatin®): A Collaborative Study in Japan.- 19. Long-Term Treatment of Resistant Acromegaly with a Somatostatin Analog (SMS 201-995, Sandostatin®).- 20. High-Dose, Long-Term, Continuous Subcutaneous Infusion of SMS 201-995 (Sandostatin®) in Acromegaly.- 21. Long-Term Therapy of Acromegaly with SMS 201-995 (Sandostatin®).- 22. Successful Treatment of Ophthalmoplegia in Acromegaly with the Somatostatin Analogue SMS 201-995 (Sandostatin®).- 23. Sandostatin® (SMS 201-995) in the Treatment of Acromegaly.- 24. Somatostatin Octapeptide (SMS 201-995, Sandostatin®) in the Medical Treatment of Acromegaly.- 25a. SMS 201-995 (Sandostatin®) Treatment of Therapy-Resistant Acromegaly.- 25b. Sandostatin® (SMS 201-995) Can Exert a Direct Analgesic Effect.- 25c. Relapsing Acromegaly Resistant to Both Bromocriptine and Sandostatin® Treatment.- 26. Consensus Discussion and Conclusions.